Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis

Imidazo[1,5-a]quinoxalines were synthesized that function as irreversible Bruton’s tyrosine kinase (BTK) inhibitors. The syntheses and SAR of this series of compounds are presented as well as the X-ray crystal structure of the lead compound 36 in complex with a gate-keeper variant of ITK enzyme. The lead compound showed good in vivo efficacy in preclinical RA models.

Graphical abstractThe synthesis and structure–activity relationships for a series of imidazo[1,5-a]quinoxalines as irreversible inhibitors of BTK are reported.Figure optionsDownload full-size imageDownload as PowerPoint slide